

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Bio-heart Biological Technology Co., Ltd.**

**上海百心安生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2185)**

## **VOLUNTARY ANNOUNCEMENT**

### **IBERIS® RDN SYSTEM PRODUCT LAUNCH AT OCC 2025**

This announcement is made by Shanghai Bio-heart Biological Technology Co., Ltd. (the **“Company”**, together with its subsidiaries, the **“Group”**) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business advancement of the Group.

The board of directors of the Company (the **“Board”**) is pleased to announce that the product launch event (the **“Event”**) for Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System (**“Iberis® RDN system”**), developed by a subsidiary of the Company, Shanghai AngioCare Medical Technology Co., Ltd.\* (上海安通醫療科技有限公司) (**“AngioCare”**), was held during the 19<sup>th</sup> Oriental Congress of Cardiology (**“OCC 2025”**) on May 31, 2025. Professor Junbo Ge from ZhongShan Hospital Fudan University, Professor Jianan Wang from The Second Affiliated Hospital Zhejiang University School of Medicine, Professor Jiguang Wang from Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Professor Xiongjing Jiang from Fuwai Hospital Chinese Academy of Medical Sciences and Professor Felix Mahfoud from University Hospital Basel chaired the Event and delivered the opening speech. The Event was hosted by Professor Jian Liu from Peking University People's Hospital. Professor Zhanying Han from the First Affiliated Hospital of Zhengzhou University, Professor Nan Jia from the Qingdao Municipal Hospital, Professor Xiongjing Jiang from Fuwai Hospital Chinese Academy of Medical Sciences, Professor Xiangqing Kong from Jiangsu Provincial Hospital, Professor Xiang Ma from the First Affiliated Hospital of Xinjiang Medical University, Professor Jianzhong Xu from Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Professor Jiancheng Xiu from Nanfang Hospital Southern Medical University, Professor Jing Yu from Lanzhou University Second Hospital, and Professor Felix Mahfoud from University Hospital Basel were invited as guest speakers and panelists for the panel discussion.

\* For identification purposes only

A live demonstration for a renal denervation (“**RDN**”) case using transradial approach (“**TRA**”) was successfully performed by Professor Juying Qian and Professor Zhifeng Yao from ZhongShan Hospital Fudan University during the Event without any complications.

As of the date of this announcement, Iberis® RDN system is the only RDN product approved globally with both TRA and transfemoral approach. TRA makes RDN safer, more effective, and cheaper. Our ultimate goal is to bring outpatient renal denervation procedures to patients around the world. Iberis® RDN system will be jointly promoted in China by Angiocare and CardioNavi Medical Technology (Wuhan) Co., Ltd., one of the business entities of the Cerebro-cardiovascular precision intervention diagnosis and treatment sector of Grand Pharmaceutical Group Limited (“**Grand Pharma**”).

### **About Grand Pharma**

Grand Pharmaceutical Group Limited (stock code: 00512.HK), abbreviated as “Grand Pharma”, is an international pharmaceutical company of technological innovation, integrating pharmaceutical technology, nuclear medicine anti-tumor diagnosis and treatment, cerebro-cardiovascular precision intervention diagnosis and treatment technology and biotechnology.

**Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** The Company cannot guarantee that Iberis® RDN system will be ultimately commercialized successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board  
**Shanghai Bio-heart Biological Technology Co., Ltd.**  
**Philip Li WANG**  
*Chairman and executive director*

Shanghai, the People’s Republic of China, June 3, 2025

*As at the date of this announcement, the Board comprises Mr. Philip Li WANG as Chairman and executive director, Mr. Yunqing WANG and Ms. Peili WANG as executive directors, and Mr. Yiqing CHEN, Mr. Xubo LU and Mr. Yifei JIANG as independent non-executive directors.*